Categories
· Health/Science
· Lung Cancer
· Diabetes
|
Jump to full article: CNN/Money, 2008-04-10
Intro: Shares of MannKind Corp. (NASDAQ:MNKD) rose in early trading Thursday, after the company said its inhaled insulin treatment has a strong safety profile with no indication of carcinogenic potential.
The shares rose 4.3% to $2.43.
The stock sank dramatically Wednesday as investors and analysts reacted to the news that competitor Nektar Therapeutics (NASDAQ:NKTR) has suspended all further research on an inhaled insulin product, a treatment that MannKind is also developing.
Jump to full article » |